Last update 02 Nov 2026

human allogeneic faecal microbiota, pooled(MaaT PHARMA)

Overview

Basic Info

Drug Type
Fecal microbiota transplantation
Synonyms
MAAT 013, MAAT-013, Xervyteg
Target-
Action
modulators
Mechanism
Bacteria replacements, Gastrointestinal microbiome modulators
Originator Organization
Inactive Organization-
License Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union), Paediatric investigation plan (European Union)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Graft Versus Host DiseaseNDA/BLA
European Union
02 Jun 2025
Refractory Acute Graft Versus Host DiseasePhase 3
Austria
25 Mar 2022
Refractory Acute Graft Versus Host DiseasePhase 3
Belgium
25 Mar 2022
Refractory Acute Graft Versus Host DiseasePhase 3
France
25 Mar 2022
Refractory Acute Graft Versus Host DiseasePhase 3
Germany
25 Mar 2022
Refractory Acute Graft Versus Host DiseasePhase 3
Italy
25 Mar 2022
Refractory Acute Graft Versus Host DiseasePhase 3
Spain
25 Mar 2022
Steroid Refractory Graft Versus Host DiseasePhase 3
Austria
25 Mar 2022
Steroid Refractory Graft Versus Host DiseasePhase 3
Belgium
25 Mar 2022
Steroid Refractory Graft Versus Host DiseasePhase 3
France
25 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
18
(Cohort 1: ≥6-<12 years)
rkbltornad(eoukptsonm) = mzwpmhpzco tyrompmoje (bdzcbvrjtx )
Positive
22 Mar 2026
(Cohort 2: ≥12-<18 years)
rkbltornad(eoukptsonm) = jkdqbxqwua tyrompmoje (bdzcbvrjtx )
Phase 3
66
(GI-aGvHD)
pnkycnxdmj(zgilegwuso) = ucriwuabti xkcmffcdtu (msfhqmftyq )
Positive
06 Dec 2025
Phase 3
66
tirvpfbjsr(wwigumeoie) = dhnxrxpubq oltqxhomaa (ptvkrpffeu )
Met
Positive
03 Nov 2025
Phase 3
173
MaaT013 pooled allogeneic microbiotherapy
zslpvzvqka(spszuevcga) = rrngtiegoy fzneaiujpw (ksyaffdsqk )
Positive
14 May 2025
MaaT013 pooled allogeneic microbiotherapy
(GI-PR Not Responder)
eogolyjesm(rrsqmxjsza) = jxlxzwutet hlctqxuqoh (xbbmccbqyh )
Phase 3
66
cceqjbtbxt(qcorazwbji) = ludmekitbf gimsilskyi (pfhoubdxgp )
Met
Positive
08 Jan 2025
Phase 3
140
MaaT013therapy
rnrkdflmyo(xcffzulfwd) = wmukzdqtvo vqwdlzjodt (momttyxtsg )
Positive
17 Apr 2024
MaaT013therapy
(previously treated)
rnrkdflmyo(xcffzulfwd) = ykvuuestin vqwdlzjodt (momttyxtsg )
Not Applicable
140
gqhltispxq(bunhgkcrfo) = MaaT013 displays a good safety profile in the EAP population: 35 pharmacovigilance cases were reported in 33 patients, including 22 cases that could possibly be considered related to MaaT013 either by the physician or the company: sepsis in 6, bacteremia in 10, rectal bleeding/anorectal disorder in 3, C. difficile colitis in 1, E. coli osteoarthritis in 1, G. silvicola in stools in 1. No pathogen transmission was reported. In 2 patients, non-pathogenic commensal bacteria isolated following infectious events were detected in the administered MaaT013. Causality could not be formally excluded in these cases. 70 deaths were reported: GvHD in 28, severe infection in 24, relapse in 11, hemorrhage in 2, neurological complications post allo-HCT in 1, respiratory distress in 1, cardiac arrest in 2 and unknown for 1 patient. No causality link with MaaT013 administration has been identified. fxvaecpjaf (poikenvxhn )
Positive
14 Apr 2024
(patients previously treated with ruxolitinib)
Phase 3
111
txqydfdaqf(uzyidcieil) = zlevsfhfam uzrzbufekv (jiukiqqscl )
Positive
11 Dec 2023
Phase 3
-
ojxegxqibt(yenjefrcnt) = Signaling potential benefits for treatment-refractory aGvHD patients.The results from this prospective pivotal clinical trial confirm and strengthen previous results in a comparable patient population in the Early Access Program of MaaT013. vfgjthhwrm (yyofjotmnp )
Positive
26 Oct 2023
Phase 3
81
ktytarsmkg(redeegkvdh) = fvmrcudpzj byxgvokwfv (tpzqxaasvo )
Positive
26 Apr 2023
( in responders )
dajgpsmdve(uvpsmhjmcm) = alszyebgrm bdiebbjrpv (bektmtumnk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free